Drug release from PLGA-based microparticles: effects of the "microparticle:bulk fluid" ratio.
The aim of this study was to better understand the importance of the "microparticle mass:bulk fluid volume" ratio during in vitro drug release measurements from PLGA microparticles. Initially porous/non-porous, ibuprofen/lidocaine/propranolol HCl-loaded systems were exposed to phosphate buffer pH 7.4 in agitated test tubes, varying the microparticle concentration from 5:1 to 20:1mg:mL. Interestingly, drug release was virtually unaffected by the "microparticle mass:bulk fluid volume" ratio in the case of initially porous, ibuprofen-loaded microparticles, exhibiting complete drug release within about 1 week. Optical microscopy, SEM, DSC and pH measurements of the bulk fluid revealed no major impact of the microparticle concentration on the systems' properties within the first couple of days. However, a more rapid and pronounced decrease in the pH of the release medium occurred after 10-14 d at elevated "microparticle mass:bulk fluid volume" ratios. This resulted in an accelerated: (i) decrease in the glass transition temperature, (ii) microparticle agglomeration, and (iii) increase in the internal and external microparticle porosity. Importantly, this phenomenon did not significantly affect drug release from initially porous, lidocaine-loaded microparticles, exhibiting complete release within about 18 d. In contrast, drug release became significantly faster at higher "microparticle mass:bulk fluid volume" ratios in the case of initially non-porous, lidocaine-loaded microparticles and initially porous, propranolol HCl-loaded systems, exhibiting complete release after 1 and 2 months, respectively. Thus, depending on the type of system, the "microparticle mass:bulk fluid volume" ratio may or may not affect the observed release kinetics in vitro. This should be carefully taken into account when defining the experimental conditions for drug release measurements from this type of advanced drug delivery systems.
Klose
D
D
College of Pharmacy, JE 2491, Univ Lille Nord de France, 3 Rue du Prof Laguesse, 59006 Lille, France.
Siepmann
F
F
Willart
J F
JF
Descamps
M
M
Siepmann
J
J
D002021:Buffers; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D006863:Hydrogen-Ion Concentration; D007052:Ibuprofen / Q000494:pharmacology; D019344:Lactic Acid / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D008012:Lidocaine / Q000494:pharmacology; D008560:Membrane Fluidity; D008863:Microspheres; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011433:Propranolol / Q000494:pharmacology
D002021:Buffers; D003692:Delayed-Action Preparations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008012:Lidocaine; D011433:Propranolol; D007052:Ibuprofen